Satellite Banner
Technology Networks Header
Thursday, October 02, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
  Videos

Return

Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
SelectBio

The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance. In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Chemists Recruit Anthrax to Deliver Cancer Drugs
With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs.
Biologists Find An Early Sign Of Cancer
Patients show boost in certain amino acids years before diagnosis of pancreatic cancer.
Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
New Approach Aims to Silence Cancer ‘Survival Genes’
Scientists at the University of York are working on a promising new approach for tackling colorectal cancer, the second most common cause of cancer-related death.
DNA in ‘Gene Deserts’ Linked with Breast Cancer
Non-coding DNA raised the risk of breast cancer by affecting the activity of key genes.
Inivata Raises £4m to Realize the Potential of ctDNA Analysis
New spin-out from Cancer Research UK launched with funding from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Reversing The Effects Of Pulmonary Fibrosis
Study shows potential for reversing the effects of pulmonary fibrosis with a microRNA mimic.
Gene Expression Patterns in Pancreatic CTCs Revealed
Distinct patterns of gene expression in several groups of CTCs were identified, including significant differences from the primary tumor that may contribute to the ability to generate metastases and prove to be targets for improved treatment of the deadly tumor.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv